As the industry pivots toward eco-design and green procurement, the whole value chain must align to bridge the gap between environmental targets and manufacturing reality.

From high-speed syringe inspection to sustainable blister production, IMA Group is heading to Düsseldorf with a portfolio of innovations aimed at streamlining the complex journey from drug product to final package.

With this definitive acquisition agreement, the CDMO will expand its presence on the global market with its first European location and will enable greater customer support.

SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

The companies have entered into the evaluation agreement to investigate whether circVec circular RNA technology can be delivered to T cells using Acuitas’ targeted lipid nanoparticles.

As smaller batch products become more prominent within drug development, companies are being required to adopt more agile, modular approaches to ensure commercial viability is achievable.

The expansion of the Swiss CDMO’s activities into the Asia Pacific area marks a significant milestone in its global growth and means it will be able to better serve pharma and biotech companies across the region.

In response to the growing demand for in-human trial material, German CDMO Vetter is expanding its clinical manufacturing network with new infrastructure in the U.S. and Austria.

The European Commission has approved dupilumab (Dupixent) as the first targeted therapy for chronic spontaneous urticaria (CSU) in children in the EU, broadening its use in type‑2‑driven inflammatory diseases.

Automation and living contamination control strategies are helping to answer some of industry’s most pressing sterile manufacturing challenges, explains Dr. Laura Moody from Syntegon.

Customized engineering and embedded sensors are helping to turn passive single-use assemblies into intelligent, data-rich assets, reveals Rich Jones from Phillips Medisize.

Automated and single-use technologies are offering companies the transparency and agility needed for the newer, more complex drugs in the pipeline, explains Mike D’Avanzo from Alcami.

While the benefits of continuous manufacturing have been well-documented, regulatory alignment and complex control systems remain barriers to universal adoption, notes Mike Fazio from L.B. Bohle.

The push for regionalized supply chains is having an impact on the CDMO landscape, with responsiveness and flexibility now considered equally important as efficiency and scale, notes Andrea Oro from ESTEVE CDMO.

The company will exhibit three key pharmaceutical processing systems for oral solid dose production at the show in New York to highlight its advances in continuous manufacturing, tablet coating, and particle processing.

As global volatility exposes the fragility of lean supply models, the industry is pivoting toward regionalized manufacturing and agile optionality to safeguard patient access.

In the current market, drug developers need to carefully balance sudden regulatory mandates with innovation while also managing costs and time efficiency, explains Meeta Kratz from Lonza Capsugel.

The new service, which is available at Lonza’s Singapore site, aims to help bioprocessing customers improve scalability, reduce manufacturing risk, and accelerate development timelines.

Aptar Pharma has entered into a technical collaboration with COVIRIX Medical to evaluate its handheld dry powder inhaler device with broad‑spectrum antiviral compounds for high‑risk respiratory viruses.

As cost pressures for drug developers persist, there is an inevitability that the industry will transition to continuous processes to overcome the limitations of traditional batch fed manufacturing.